anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine; pharmaceuticals.SUBSTANCE: present invention refers to compositions and pharmaceutical preparations for treating or preventing central and peripheral nervous system disorders. Composition contains at least one active pharmaceutical ingredient selected from 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide and its pharmaceutically acceptable salts, and at least one excipient which is selected from excipients and binders. Said active pharmaceutical ingredient is present in a granular form. Volumetric density of composition exceeds 0.2 g/ml. Also described is a dosage form selected from tablets and capsules. Methods of preparing the composition and the dosage form are also described.EFFECT: compositions of the invention containing the granulated said active pharmaceutical ingredient are characterized by high bulk density, compressibility and fluidity.31 cl, 4 tbl, 3 ex
The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
FIELD: molecular biology, biotechnology, medicine. SUBSTANCE: invention describes the purified and isolated molecule of nucleic acid that is able to encode protein D15 of an external envelope of bacterium Haemophilus. Molecule can be inserted into recombinant plasmid or recombinant vector. Invention describes also the protein encoded by nucleic acid. The use of invention ensures to obtain vaccines for treatment and diagnosis of diseases caused by Haemophilus. EFFECT: vaccine preparing. 23 cl, 17 dwg, 9 tbl, 13 ex
PURPOSE: A composition containing MMP-9(metalloproteinase-9) is provided to increase implantation and pregnancy rate. CONSTITUTION: A composition for implantation or pregnancy of animal fertilized egg contains MMP-9 as an active ingredient. The animal is mammal. The mammal includes human, bovine, pig, horse, sheep, rabbit, elephant, monkey, hamster, or rat. The fertilized egg is obtained by in vitro fertilization. The egg is treated with MMP-9 and transplanted before transplantation. The pregnancy is in vitro fertilization-assisted pregnancy or artificial fertilization-assisted pregnancy.
All patients enrolled in the study will be treated with nab-paclitaxel during radical radiotherapy following induction chemotherapy. The doses are increased progressively from 180 mg/m² to a maximum of 260 mg/m².
There is evidence that cancer diagnosis and treatment during young adulthood puts survivors at risk for a number of medical and psychosocial difficulties including cardiovascular disease, second cancers and psychological distress. The proposed research is aimed at developing a physical activity and relaxation intervention for young adult cancer survivors in order to address some of their medical and psychosocial risks. The objective of the study is to pilot test a 12-week physical activity and relaxation intervention in this population. We hypothesize that the intervention will be feasible for and acceptable to young adult cancer survivors. We also hypothesize that the intervention group will demonstrate increased levels of physical activity, improved mood and reduced fatigue relative to the wait list control group at the 12-week and 24-week follow-up assessments; statistically significant differences may not be found due to the small sample size, however. In addition, we will conduct exploratory tests of intervention effects on fitness, flexibility, body mass, and waist circumference. Sixty participants will be recruited for the pilot study. Participants will be randomly assigned to receive a 12-week physical activity and relaxation intervention or to a wait list control group. Intervention group participants will receive 12 weeks of behavior change counseling, based on the Transtheoretical Model and Social Cognitive Theory, to help them adopt a program of brisk walking and learn mindfulness meditation. They will also be given access to an online discussion group. Participants in both arms of the study will be assessed at baseline, 12 weeks, and 24 weeks. Following the 24-week assessment, wait list control participants will offered the 12-week intervention and one additional assessment (i.e., at 36 weeks). Data will be collected on intervention feasibility (e.g., number of counseling sessions delivered) and acceptability (e.g., general satisfaction ratings). ANCOVAs will be used to conduct preliminary tests of intervention effects (e.g., on physical activity, mood, and fatigue).
Participants in the healthy control group will not participate in any gait training. Healthy control participants will only be asked to complete 3 testing sessions.
Rhino sinusitis is one of the most common health-care problems worldwide and its prevalence and incidence is increasing. Chronic Sinusitis is a big health problem worldwide that affects almost 15% of humans. The most affected sinus is the maxillary sinus as its drainage orifice through the hiatus semilunaris is badly placed near the roof of the sinus. The first line of treatment for sinusitis is mostly medical drugs including antimicrobial drugs, decongestants, nasal sprays, corticosteroids, and antihistamine drugs which can effectively dry the mucus. Physical therapy also offers a variety of treatment approaches for sinusitis. It includes various electrotherapy modalities, manual drainage techniques, suboccipital release for sinus headaches, needling, and rhino flow therapy. In spite of many studies and treatment approaches done on sinusitis, there are limitations faced in evidence of which approval is most effective, The objective of our study is to investigate the effect of physical therapy protocol in people with chronic maxillary sinusitis.sixty six patients with chronic maxillary sinusitis will be allocated randomly to three groups; one group will receive physical therapy protocol, second one will receive medication only and the third one will receive physical therapy protocol and medication for four weeks.
Human papillomavirus 16 (HPV16) infection is the leading cause of cervical cancer. The current mainstream method for detecting HPV16 is quantitative real-time PCR (qPCR). However, due to its time-consuming nature and reliance on expensive qPCR instruments, there is growing interest in more convenient, rapid and private approaches such as recombinase polymerase amplification (RPA). In this study, we innovated an effective method for HPV16 detection by integrating a RPA system with lateral flow strip (LFS) detection. Primers with optimal efficiency and specificity were designed, and false positive signals caused by dimers were eliminated by reducing the probe concentration. The RPA-LFS method demonstrates high sensitivity and specificity, capable of detecting 230 copies per reaction of HPV16 within 25 min without cross-reactivity to other subtypes. It exhibits good tolerance, remaining unaffected by 1.0% miconazole, 0.5% tioconazole and 1.0% hemoglobin. The results of clinical samples detected by this method were consistent with those of qPCR. The method provides a practical reference for HPV16 diagnosis and can be valuable in home and resource-limited settings, contributing to the reduction of cervical cancer incidence.
Currently, providing patients, particularly those with acute myocardial infarction (AMI), with comprehensive cardiac rehabilitation (CR) has been challenging because of the inadequate availability of medical resources in developing countries. To ensure balance between disease instability and early rehabilitation, strategies for facilitating professional and comprehensive CR opportunities for patients with AMI must be explored.A prospective cohort study was carried out on 1,533 patients with AMI who were admitted to a tertiary hospital between July 2018 and October 2019. Following the principle of voluntarism, 286 patients with AMI participated in home-center-based CR (HCB group), whereas 1,247 patients received usual care (UC group). The primary endpoint of this study was the occurrence of cardiovascular events at 30 months after AMI. Moreover, the study analyzed factors that influence participation rate and effectiveness of the CR model.After analysis, a significant difference in the occurrence of cardiovascular endpoints between the HCB group and the UC group was observed (harzard ratio, 0.68 [95%CI, 0.51-0.91], P = 0.008), with participation in home-center-based CR being an independent influencing factor. Multivariate regression analysis revealed age, gender, smoking history, triglyceride levels, and ejection fraction as independent factors that influence participation rate. Female gender, peak oxygen uptake per kilogram body weight, and ventilation/carbon dioxide production slope were identified as factors that affect the effectiveness of the CR model.In the context of developing countries, this study demonstrates that the home-center-based CR model is efficient and analyzes factors that influence participation rate and effectiveness of the model. These findings provide practical insights for further development of CR programs.
Allodynia is a neuropathic pain triggered by a normally painless stimulus: for example, a slight touch on the skin or slight sensation of hot or cold is extremely painful. Rehabilitation is long and uncertain. Protecting the painful area from stimuli is a priority of care. This type of care is complex and challenging for the care team: the pain caused in manufacturing a classic molded orthosis is unbearable for the patient, and the orthosis has a limited lifetime, and experience shows that it is not possible to produce two identical splints. The present study consisted in creating protective splints by 3D printing, designed from data collected with the 3D surface scanner used in our forensic imaging and anthropology unit. The pros and cons of the 3D orthosis versus standard molded orthoses from the point of view of the patient and the practitioner are discussed, with evaluation of related indications of this technology.
1399632 Diuretic &c medicines LEO PHARMACEUTICAL PRODUCTS Ltd AS (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) 6 July 1973 [13 July 1972 7 Nov 1972 24 Jan 1973] 32909/72 51384/ 72 and 3658/73 Heading A5B [Also in Division C2] Pharmaceutical compositions having diuretic and saluretic actions contain (I) as active ingredient in which R 1 is a substituted or unsubstituted C 1 -C 6 alkyl, alkenyl or alkynyl radical, or a C 1 -C 3 alkyl radical substituted with a phenyl, substituted phenyl or an unsubstituted or substituted 5- or 6-membered heterocyclic radical containing not more than two hetero atoms selected from oxygen, sulphur and nitrogen atoms; R 2 is a substituted or unsubstituted phenyl radical; X and Y are each an oxygen or sulphur atom; and pharmaceutically acceptable, non-toxic salts of the carboxylic acid of formula I; and esters thereof with cyanomethanol, benzyl alcohol, and C 1 -C 6 alkanols. The compositions may further contain other therapeutic compounds applied in the treatment of, for example oedemas and hypertension, besides the well-known auxiliary agents. Such other compounds may be, for instance, Veratrum- or Rauwolfia alkaloids, e.g. reserpine, rescinnamine or protoveratrine or synthetic hypotensive compounds, e.g. hydralazine, or other diuretics and saluretics, such as the wellknown benzothiadiazines, e.g. hydroflumethiazide, bendroflumethiazide. Potassium-sparing diuretics, e.g. triamterene, may also be used in the preparation of the compositions. For some purposes it may be desirable to add small amounts of aldosterone antagonists, e.g. spironolactone. Administration is orally, parenterally or enterally.
[GB1399632A]
Prior to initiating treatment with EQUETRO, test patients with ancestry in genetically at-risk populations for the presence of the HLA-B*1502 allele. The high resolution genotype test is positive if one or two HLA-B*1502 alleles are present. Avoid use of EQUETRO in patients testing positive for the allele, unless the benefit clearly outweighs the risk [see Boxed Warning, Warnings and Precautions (5.1)]. 

Complete pretreatment blood counts, including platelets and possibly reticulocytes and serum iron, should be obtained as a baseline. If a patient in the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of EQUETRO should be considered if any evidence of significant bone marrow depression develops [see Warnings and Precautions (5.2)].

Baseline and periodic evaluations of liver function, particularly in patients with a history of liver disease, must be performed during treatment with EQUETRO because liver damage may occur. Discontinue EQUETRO in cases of aggravated liver dysfunction or active liver disease [see Warnings and Precautions (5.10)]. 

Baseline and periodic eye examinations, including slit-lamp, funduscopy, and tonometry, are recommended since many phenothiazines and related drugs have been shown to cause eye changes [see Warnings and Precautions (5.13)].

Baseline and periodic complete urinalysis and BUN determinations are recommended for patients treated with this agent because of observed renal dysfunction.
FIELD: cosmetics. SUBSTANCE: composition is designated for treatment of keratin-containing materials, mainly hair. It can be used in compositions used for hair stacking to make form, volume and comb fixing for hair. The composition consists of cosmetically and dermatologically acceptable medium where at least one grafted silicone copolymer containing polysilicone moiety and silicon-free organic chain moiety present. One of two parts is the main part of polymer and another one is grafted on the main part. Also, the composition has at least one combination including at least one anionic polymer and at least one cationic polymer. The method of treatment of keratin-containing materials, in part hair, is claimed. The method involves applying the claimed composition on hair. After the composition applying hair can be rinsed with water. EFFECT: improved properties of the composition. 46 cl, 2 ex
Safety and efficacy of AXERT® in pediatric patients under the age of 12 years have not been established. The pharmacokinetics, efficacy, and safety of AXERT® have been evaluated in adolescent patients, age 12 to 17 years [see Clinical Pharmacology (12.3) and Clinical Studies (14.2)].

In a clinical study, AXERT® 6.25 mg and 12.5 mg were found to be effective for the relief of migraine headache pain in adolescent patients age 12 to 17 years. Efficacy on migraine-associated symptoms (nausea, photophobia, and phonophobia) was not established. The most common adverse reactions (incidence of ≥1%) associated with AXERT® treatment were dizziness, somnolence, headache, paresthesia, nausea, and vomiting [see Adverse Reactions (6.1)]. The safety and tolerability profile of AXERT® treatment in adolescents is similar to the profile observed in adults.

Postmarketing experience with other triptans include a limited number of reports that describe pediatric patients who have experienced clinically serious adverse events that are similar in nature to those reported rarely in adults.
PROBLEM TO BE SOLVED: To obtain a powdery oil or fat compsn. which is excellent in flowability and can be quickly dissolved in water without causing turbidity by mixing a powder-forming base in the form of a powder or granules with a specified amt. of an oil or fat and spray coating the resultant oil or fat-contg. powder with an aq. coating agent soln. contg. gelatine and a film hardness adjusting agent in a specified ratio. SOLUTION: 40-95 pts. powder-forming base comprising at least one powdery or granular material selected pref. from among starch derivs., gum arabic, and soy bean polysaccharides is mixed with 5-60 pts. oil or fat. The resultant oil or fat-contg. powder is spray coated with an aq. coating agent soln. contg. gelatine pref. having a gelly strength of 50-350 bloom and at least one film hardness adjusting agent selected pref. from among polyhydric alcohols (e.g. glycerin or sorbitol), saccharides (e.g. sucrose), agar, glucomannan, and carrageenan in a ratio of gelatine to the adjusting agent of (1:20)-(50:1). A liq. or solid oil or fat used in food, cosmetics, medicines, etc., can be used as the oil or fat.
The investigators are planning to conduct a pilot descriptive study involving Foothill Medical Centre (FMC), Calgary. Research ethics approval will be obtained. The trial will also be registered at clinicaltrials.gov

The sessions will take place at the labor and delivery floor (L\&D) simulation lab at FMC. The proposed time for study completion is 18 months. No follow up is required for this study. The data will be collected by one of the investigators (Dr. Fatemah Qasem). In addition, the participants performance will be video recorded for further data collection and revision by the investigator team.

On the day of the simulation session, the participants will be pre-briefed to the simulation room, mannequin, and the equipment but will be naïve to the simulation scenario. The simulation scenario will involve amniotic fluid embolism (AFE) in a term pregnant parturient with singleton pregnancy. The patient will have a working epidural catheter in situ for labor analgesia and an 18G IV line. The parturient will develop cardiopulmonary collapse due to AFE requiring ACLS.

The scenario will be scripted by investigator team members. The same scenario will be used at both centers (FMC and RGH). The script will include the initial clinical vignette; vital signs; patient weight; laboratory values; planned changes in clinical status, including what and when decompensations should occur (eg, 4 minutes into scenario, the patient will progress to pulseless VT); and planned responses to actions by participants. Time 0 will be referred to the onset of the decompensation. For maintaining realism, little interaction will occur between participants and evaluators. If no one remembers to call the code team, then the emergency is managed with only L\&D staff. Although the primary focus of this study is to assess the quality of resuscitation delivered by first responders before the code team's arrival, the exercise will also allow to assess the resuscitation skills of obstetric care unit team. The scenario will end at skin incision for delivery of the fetus. Thirty minutes will be used for debriefing time as part of the hospital staff education. Data collected during the debriefing, and discussion points will used for quality improvement purposes and will not be used as part of the study results.
The non-crossover group of the study will follow 20 patients for the entire 17 weeks and participants in this arm will not be crossed over, will not have a washout period, and will consume R Drink for the total duration of the study. If patients in this arm wish to continue on the R Drink, for 6 additional months they may do so. At the end of the optional 6 months these patients will have a repeat research transthoracic echocardiogram. Data collection will occur at baseline, week 8, and week 17. An additional 6 month data collection time point will occur for patients in the third arm opting to continue R Drink.
Raoultella planticola is a Gram-negative, aerobic, nonmotile bacterium that is ubiquitous in the environment usually implicated in opportunistic infections. There have been very few reported cases of Raoultella planticola infection in the pediatric population. Most of these reports have been in cases of neonatal septicemia. This case report describes a case of a 3-day-old Hispanic full-term male that presented with recalcitrant hyperbilirubinemia despite maximal phototherapy found to have urinary tract infection with Raoultella planticola on multiple cultures. The patient's hyperbilirubinemia appropriately responded to treatment of the UTI. This report highlights that, albeit rare, neonatal UTI can present as recalcitrant hyperbilirubinemia. Raoultella planticola is a rare organism that is normally found in the environment but may be a bona fide etiologic agent in neonatal UTI.
Participants in this intervention group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is Cognitive Bias Modification Training for Attention. It is designed to reinforce attention away from ACS threat-related stimuli (e.g., "death," "chest pain") and toward neutral stimuli (e.g., "curve," barn doors"). The second task is Cognitive Bias Modification Training for Interpretation. It is designed to train participants to appraise ambiguous information that is potentially related to ACS threat as benign.
After exercises completed, individuals receive percussion therapy on quadriceps for 10 minutes for both sides. Afterwards individuals will be evaluated again.
Renal fibrosis is the result of all chronic kidney diseases and is becoming a major global health hazard. Currently, traditional treatments for renal fibrosis are difficult to meet clinical needs due to shortcomings such as poor efficacy or highly toxic side effects. Therefore, therapeutic strategies that target the kidneys are needed to overcome these shortcomings. Drug delivery can be attained by improving drug stability and addressing controlled release and targeted delivery of drugs in the delivery category. By combining drug delivery technology with nanosystems, controlled drug release and biodistribution can be achieved, enhancing therapeutic efficacy and reducing toxic cross-wise effects. This review discusses nanomaterial drug delivery strategies reported in recent years. Firstly, the present review describes the mechanisms of renal fibrosis and anti-renal fibrosis drug delivery. Secondly, different nanomaterial drug delivery strategies for the treatment of renal injury and fibrosis are highlighted. Finally, the limitations of these strategies are also discussed. Investigating various anti-renal fibrosis drug delivery strategies reveals the characteristics and therapeutic effects of various novel nanosystem-derived drug delivery approaches. This will serve as a reference for future research on drug delivery strategies for renal fibrosis treatment.
Collagenase (I) produced by Flavobacterium spec CRZV.1 and having the following characteristics is new:- a) it has a mol . wt. of 83000-105000 daltons; b) an isoelectric pH of 7.9; c) optimal collagenolytic activity at pH 7.6 in 0.05M tris HCl 0.003M CaCl2 buffer at -30deg.C; d) it does not have non-specific proteolytic activity and is weakly inhibited by cysteine and thiol function blocking agents. Used for the tenderisation of meat and in medicine, for the treatment of burns in healing of wounds in dental transplantation, for resorption of discal hernias and the dissociation of cells. Prepn. of (I) comprise fermentation of Flavobacterium spec. CRZV.1 in a suitable medium of 15-35 deg.C. and 30 deg.C. and pH 7-9 pref. 7-6, followed by extraction and purification Suitable media are based on collagem or substances having similar proteic sequences, e.g. polymeric collagem, thermally denatured calhogen (gelatins) or meat extracts, and contain 1-25g/l of material esp. 10g/l of meat extract or 12g/l of collagens. The culture medium also contains vitamins, usually yeast extracts in amounts of 0.1-25g./l, esp. 2.5g/l.